Learn More
Meropenem is used to manage postneurosurgical meningitis, but its population pharmacokinetics (PPK) in plasma and cerebrospinal fluid (CSF) in this patient group are not well-known. Our aims were to (i) characterize meropenem PPK in plasma and CSF and (ii) recommend favorable dosing regimens in postneurosurgical meningitis patients. Eighty-two patients were(More)
OBJECTIVE Meropenem is important for management of postneurosurgical meningitis, but the data about its penetration into cerebrospinal fluid (CSF) are inadequate. This prospective, open-label study investigated the pharmacokinetic profile of meropenem in patients with postneurosurgical meningitis, especially its CSF penetration. METHODS A total of 82(More)
BACKGROUND Tigecycline, a first-in-class broad-spectrum glycylcycline antibiotic, has broad-spectrum in vitro activity against bacteria commonly encountered in complicated intra-abdominal infections (cIAIs), including aerobic and facultative Gram-positive and Gram-negative bacteria and anaerobic bacteria. In the current trial, tigecycline was evaluated for(More)
The pygmephoroid mite, Brennandania lambi (Krczal), is the most serious mite pest of mushroom production in Shanghai. China. This mite could not develop and reproduce on the mycelia of Lentinus edodes, Flammulina velutipes, Pleurotus ostreatus or Pleutotus sajor-caju, but 12–20% of the females survived 15 to 31 days on these hosts, whereas all mites died(More)
Laboratory and field studies were conducted to evaluate freezing as a control measure against Brennandania lambi (Krczal) which infests cultivated mushrooms (Agaricus bisporus) in Shanghai primarily through contaminated spawn. Laboratory experiments showed that exposure of contaminated spawn at -10° C for 24 h killed all stages of B. lambi. These mites(More)
BACKGROUND/PURPOSE To compare the clinical efficacy and safety of nemonoxacin with levofloxacin in treating community-acquired pneumonia (CAP) in a Phase II clinical trial. METHODS One hundred ninety-two patients with CAP were randomized to receive oral nemonoxacin (500 mg or 750 mg) or levofloxacin (500 mg) once daily for 7-10 days. Clinical and(More)
  • 1